These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7222188)

  • 1. Chloramphenicol hemodialysis clearance.
    Blouin RA; Erwin WG; Dutro MP; Bustrack JA; Rowse KL
    Ther Drug Monit; 1980; 2(4):351-4. PubMed ID: 7222188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency.
    Grafnetterová J; Vodrázka Z; Jandová D; Schück O; Tomásek R; Lachmanová J
    Clin Nephrol; 1976 Oct; 6(4):448-50. PubMed ID: 975643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hemodialysis on total body clearance of chloramphenicol.
    Slaughter RL; Cerra FB; Koup JR
    Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
    Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
    Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Ganansia J; Bianchetti G; Morselli PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction.
    Odar-Cederlöf I; Bjellerup P; Williams A; Blagg CR; Twardowski Z; Ting G; Kjellstrand CM
    Hemodial Int; 2006 Oct; 10(4):394-8. PubMed ID: 17014518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodialysis clearance of total and unbound lidocaine.
    Jacobi J; McGory RW; McCoy H; Matzke GR
    Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodialysis of mefenamic acid in uremic patients.
    Wang LH; Lee CS; Marbury TC
    Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
    Asad SN; Olmer AJ; Letteri JM
    Miner Electrolyte Metab; 1984; 10(5):333-6. PubMed ID: 6493162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Migliacci R; Falcinelli F; Imperiali P; Floridi A; Nenci GG; Gresele P
    Ital Heart J; 2004 May; 5(5):371-7. PubMed ID: 15185901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
    Teigen MM; Duffull S; Dang L; Johnson DW
    J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
    Tarakçioğlu M; Erbağci AB; Usalan C; Deveci R; Kocabaş R
    Mediators Inflamm; 2003 Feb; 12(1):15-9. PubMed ID: 12745544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan clearance in renal failure and hemodialysis.
    Ullery LL; Gibbs JP; Ames GW; Senecal FM; Slattery JT
    Bone Marrow Transplant; 2000 Jan; 25(2):201-3. PubMed ID: 10673681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.